Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tenalisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rhizen Announces Data Presentations at ESMO 2022 for Its Clinical Stage Assets
    Rhizen Announces Data Presentations at ESMO 2022 for Its Clinical Stage Assets

    09 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220909005131/en

    BUSINESSWIRE
    09 Sep 2022
    Share Share
    Rhizen Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530)
    Rhizen Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530)

    13 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211013005802/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-II-Study-of-Tenalisib-RP6530-in-Locally-Advanced-or-Metastatic-Breast-Cancer-Patients

    BUSINESSWIRE
    13 Oct 2021
    Share Share
    Rhizen Begins Dosing in Phase II Study of Tenalisib in Breast Cancer
    Rhizen Begins Dosing in Phase II Study of Tenalisib in Breast Cancer

    13 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211013005802/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-II-Study-of-Tenalisib-RP6530-in-Locally-Advanced-or-Metastatic-Breast-Cancer-Patients

    BUSINESSWIRE
    13 Oct 2021
    Share Share
    Alembic Pharma share price gains as associate company enters agreement Tenalisib
    Alembic Pharma share price gains as associate company enters agreement Tenalisib

    12 Oct 2020

    // MONEYCONTROL

    https://www.moneycontrol.com/news/business/stocks/alembic-pharma-share-price-gains-as-associate-company-enters-agreement-to-develop-tenalisib-5956431.html

    MONEYCONTROL
    12 Oct 2020
    Share Share